Parkinson's disease is characterized by the degeneration of dopaminergic pathways projecting to the striatum. These pathways are implicated in reward prediction. In this study, we investigated reward and punishment processing in young, never-medicated Parkinson's disease patients, recently medicated patients receiving the dopamine receptor agonists pramipexole and ropinirole and healthy controls. The never-medicated patients were also re-evaluated after 12 weeks of treatment with dopamine agonists. Reward and punishment processing was assessed by a feedback-based probabilistic classification task. Personality characteristics were measured by the temperament and character inventory. Results revealed that never-medicated patients with Parkinson's disease showed selective deficits on reward processing and novelty seeking, which were remediated by dopamine agonists. These medications disrupted punishment processing. In addition, dopamine agonists increased the correlation between reward processing and novelty seeking, whereas these drugs decreased the correlation between punishment processing and harm avoidance. Our finding that dopamine agonist administration in young patients with Parkinson's disease resulted in increased novelty seeking, enhanced reward processing, and decreased punishment processing may shed light on the cognitive and personality bases of the impulse control disorders, which arise as side-effects of dopamine agonist therapy in some Parkinson's disease patients.

A method is suggested for the synthesis of multicomponent peptide mixtures. The method is a solid phase synthesis modified in order to give a closely equimolar mixture of peptides with predetermined sequences. The main point of modification is that before every coupling cycle the resin is divided into equal parts and each portion is coupled with a different amino acid. Then the portions are mixed and before the next coupling cycle the resin is again distributed into equal portions. The method is illustrated by the synthesis of a mixture of 27 tetrapeptides and that of 180 pentapeptides.

No abstract

γ-Valerolactone (GVL) has been proposed as a sustainable liquid, and could be used for the production of hydrocarbons by using both homogeneous and heterogeneous catalytic systems. The selective reduction of levulinic acid (LA) to GVL is a key transformation for biorefinery concepts based on platform molecules. We report a detailed investigation of the conversion of LA to GVL using molecular hydrogen in the presence of a catalyst in situ generated from Ru(acac) 3 , and electronically and sterically characterized alkyl-bis(m-sulfonated-phenyl)-and dialkyl-(m-sulfonated-phenyl)phosphine (R n P(C 6 H 4 -m-SO 3 Na) 3−n (n = 1 or 2; R = Me, Pr, iPr, Bu, Cp) ligands. The hydrogenation experiments were performed in the range of 5-100 bar H 2 at 140 °C using 0.016 mol% catalyst and 5-20 eqv. of ligand. The effects of hydrogen pressure and Ru/ligand ratio on the LA conversion were determined. The nBuP(C 6 H 4 -m-SO 3 Na) 2 (χ = 12.5, θ Tol = 153°) showed the highest activity achieving turnover numbers up to 6200 with a yield and selectivity higher than 99% in a solvent, chlorine and promoter free reaction mixture. The catalyst was successfully recycled for six consecutive runs without loss of activity. The characterization of sulfonated and non-sulfonated phosphines indicated that the sulfonation had no significant effect on the steric and electronic properties of the ligands.Scheme 1 † Electronic supplementary information (ESI) available. See

No abstract